Peptide payment processing: the operator guide
- Peptide payment processing means a high-risk merchant account at a specialist acquirer, never Stripe, Square, or PayPal, which all exclude peptides by policy.
- Underwriters read your website, labels, and reason-code mix, so compliance is the lever that moves your rate and reserve more than volume does.
- Single-brand operators belong at a specialist ISO; multi-brand portfolios are where a parent-account orchestration layer starts to earn its higher rate.
On this page
A peptide founder messaged us at the start of the year: store live, first orders flowing through Stripe, everything working. We told him to read this guide before he scaled, because the part that was working was the part about to break. Six weeks later the Stripe freeze arrived on schedule. Peptide payment processing is not hard because the technology is complex; it is hard because the mainstream processors will not touch the vertical and the ones that will price the risk into every line of the contract. This guide is the whole picture for an operator: who approves you, what underwriters actually check, how reserves and chargebacks work, and how to structure once you have more than one brand. We orchestrate on top of these accounts, so we will be straight about where we fit and where we do not.
Why mainstream processors decline peptides
Stripe, Square, PayPal, Braintree, Shopify Payments, Venmo, and Cash App for Business all exclude peptides under their acceptable use policies. This is an objective fact, not a conspiracy. Their risk models are built for low-risk merchants and a peptide store does not fit, so accounts that slip through get closed within three to six months once review reads the product pages.
The practical takeaway: do not spend application attempts on processors that will close you. Treat the mainstream gateways as a wall and route around it. Our comparisons on Stripe and PayPal spell out the policy language so you can stop second-guessing.
What peptide processing actually requires
A working peptide stack has three parts: a high-risk merchant account at a specialist acquirer, a gateway that vaults cards and runs recurring billing, and a website that survives underwriting review. The gateway is almost always Authorize.net or NMI. The acquirer is a peptide-friendly ISO such as EasyPayDirect, Durango, Corepay, Soar, or PayKings.
The right merchant category code matters here. Miscoded peptide stores draw scrutiny and sometimes get repriced after the fact when the acquirer notices the mismatch. Get the MCC right at onboarding rather than fighting it later.
What underwriters actually check
Underwriting a peptide account is mostly a website review plus a numbers review. The underwriting team looks at:
- Labels and claims. Research-use framing versus human-consumption language. Dosing instructions for people are a fast decline.
- Disclaimers. An FDA-not-evaluated statement where supplement claims appear, plus research-use disclaimers where applicable.
- Refund and terms visibility. A clear, findable refund policy lowers your dispute risk in their model.
- COA availability. Certificates of analysis per SKU signal a real operation.
- Reason-code mix. Product-quality disputes drop you faster than fraud disputes, so they weight the distribution, not just the ratio.
All of this moves your outcome more than a 20-basis-point rate difference. Compliance is the cheapest lever you control. The website compliance checklist turns this into a pre-application punch list.
Rates, reserves, and the real cost
Interchange on card-not-present credit runs roughly 1.65 to 2.60% plus about $0.10 per transaction, identical for every ecommerce merchant. The peptide premium is entirely in the markup and the reserve. Expect a 3.5 to 4.5% effective rate single-brand at a specialist ISO, with a 10 to 15% rolling reserve held 180 days in year one.
| Item | Single-brand specialist ISO | multiflow (3+ brands) |
|---|---|---|
| Effective rate | 3.5-4.5% | 5.5-7.5% + setup |
| Reserve | 10-15% rolling / 180d | 5-10% rolling |
| Gateway | Auth.net / NMI | Auth.net / NMI (orchestrated) |
| Best at | 1-2 brands | 3+ brands |
| Onboarding | 5-10 business days | 14-30 days |
The reserve is the larger cost most operators ignore. On $100,000 monthly volume, a 12% reserve parks $12,000 of working capital for six months. Price it in.
Gateway versus acquirer: know which one is which
Operators conflate these two and it costs them in the wrong conversations. The gateway is the software that captures the card, vaults the token, and runs recurring billing; Authorize.net and NMI are gateways. The acquirer is the bank relationship that actually approves your business, holds your reserve, and decides whether you keep processing; EasyPayDirect, Durango, and the rest are ISOs that place you with an acquiring bank.
Why it matters: the gateway almost never closes you, the acquirer does. When people say a processor froze them, they mean the acquiring side pulled the plug, usually over chargebacks or a website review. You can keep the same Authorize.net gateway and move acquirers, or run one gateway across several acquirers, which is exactly the failover an orchestration layer manages. See the payment gateway and merchant account entries for the precise definitions, because using the wrong word at intake makes you sound new.
Where SARMs, research chems, and nutra sit next to peptides
Most peptide operators do not sell only peptides. A typical book carries some SARMs, the occasional research chemical, and a nutraceutical line for the customers who want a compliant product. Each sits in a different underwriting bucket, and mixing them on one account without telling the acquirer is how a clean approval turns into a mid-term repricing.
- SARMs underwrite tighter than peptides; some peptide-friendly acquirers stop at SARMs entirely. If SARMs are a real line, say so up front and read the SARMs industry page.
- Research chemicals are the strictest of the group and narrow your acquirer list sharply. Be specific about what you actually sell.
- Nutraceuticals are the softest, and a clean nutra line can stabilize a book, but supplement claims still draw FDA-not-evaluated disclaimer scrutiny. The nutraceuticals page covers it.
The honest move is to declare your full catalog at onboarding. An acquirer that approves you knowing the mix will not surprise-reprice you; one that finds an undisclosed SARMs line three months in will.
Chargebacks: the number that ends accounts
Your chargeback ratio is the metric that gets you frozen. Visa VAMP flags excessive at 0.9% and Mastercard ECM at 1.0%, with severe tiers near 1.8 to 2.0%. Cross a threshold and the acquirer pauses or closes you, and a closure can land you on the MATCH list for five years.
Keep the ratio down with clear billing descriptors so customers recognize the charge, an easy cancel flow on subscriptions, disciplined representment on every dispute, and tuned fraud filters at checkout. Our pieces on refund-policy chargeback reduction and fraud-filter tuning go deep on each.
Structuring for one brand versus many
A single peptide brand should run on one merchant account at a specialist ISO. That is the cheapest, fastest, simplest setup and we send single-brand operators there directly. Do not over-engineer it.
The math changes with portfolio size. Every additional brand on its own account duplicates the setup fee, gateway fee, monthly minimum, reserve, and statement, plus the reconciliation labor of tracking them all. Around three to five brands, that duplication can cost more than a single parent account with per-brand descriptors at a higher per-transaction rate. That crossover is the only place multiflow belongs, and you can read how it works on the peptide operators page or in how it works.
Settlement, payouts, and the cash you can actually touch
The rate and reserve get all the attention, but your payout schedule determines the cash you can actually spend this week. Standard settlement on a specialist peptide account runs T+1 to T+2, similar to mainstream gateways, but the reserve carves a slice off every batch before it lands.
Picture $100,000 of monthly peptide volume at a 4.1% effective rate and a 12% rolling reserve. Roughly $4,100 goes to fees, $12,000 is held in the rolling pool until the 180-day window fills, and the rest settles to your bank on the T+1/T+2 cadence. Once the rolling window is full, old reserve releases as new accrues, so the held balance stabilizes rather than growing forever. New operators routinely underestimate the first-180-day cash squeeze because the reserve is building toward steady state during exactly the months they are funding inventory and ads. Model that ramp before you scale spend.
One more reporting note: at year end your acquirer files a 1099-K on your gross processing volume, and the current reporting threshold is $5,000. Gross, not net, so the number on the form is larger than what hit your bank after fees and reserve. Reconcile it against your own ledger rather than your deposits.
A sane sequence for getting started
- Fix the website first: labels, disclaimers, refund policy, COAs. Underwriting reads it.
- Pick a gateway (Authorize.net or NMI) and apply to two or three specialist ISOs in parallel.
- Compare the actual contracts, not the verbal quotes. Watch the reserve and the ETF.
- Launch clean: stagger any subscriber migration, keep funnels disciplined for the first 90 days, and watch the dispute queue daily.
- Reassess structure once you cross three brands.
Where to go from here
If you are a single-brand peptide operator, the peptide industry overview and the specialist-ISO route are your starting point, and you may not need us at all. That is fine; we would rather you have the right setup than the one we sell.
If you are running multiple peptide brands and the reconciliation across separate accounts has become the actual job, send us the 12-question application for an honest fit check. We will run your real numbers and tell you whether a parent account beats your current stack or whether you are already on the cheapest honest option. No hard pull, and no pitch if it does not fit.